Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
N
Nabil Adra, MD
Primary Investigator
Overview
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with hormone-sensitive prostate cancer previously treated with docetaxel that has spread to other parts of the body.
Description
The purpose of this study is to assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with castration-resistant prostate cancer (CRPC) that have previously received docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) can improve progression-free survival (PFS) compared to abiraterone acetate alone.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
prostate cancer,castration-resistant prostate carcinoma,metastatic prostate carcinoma,prostate adenocarcinoma
-
Age: Between 18 Years - 100 Years
-
Gender: Male
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
- Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:Participants will not be paid for their participation.
Updated on
20 Apr 2024.
Study ID: 1805551737 (EA8153)